Jardiance and Enstilar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Jardiance and Enstilar. Common interactions include diabetic ketoacidosis among females and calculus urinary among males.

The phase IV clinical study analyzes what interactions people who take Jardiance and Enstilar have. It is created by eHealthMe based on reports of 10 people who take Jardiance and Enstilar from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 22, 2022

10 people who take Jardiance and Enstilar together, and have interactions are studied.


What is Jardiance?

Jardiance has active ingredients of empagliflozin. eHealthMe is studying from 28,961 Jardiance users for its effectiveness, alternative drugs and more.

What is Enstilar?

Enstilar has active ingredients of betamethasone dipropionate; calcipotriene. eHealthMe is studying from 1,138 Enstilar users for its effectiveness, alternative drugs and more.

Number of Jardiance and Enstilar reports submitted per year:

Jardiance and Enstilar drug interactions.

Common Jardiance and Enstilar drug interactions by gender *:

female:

  1. Diabetic ketoacidosis
  2. Drug hypersensitivity
  3. Eczema
  4. Endometrial cancer
  5. Fall
  6. Gait disturbance
  7. Immunosuppression
  8. Injection site pain
  9. Joint injury
  10. Limb injury

male:

  1. Calculus urinary
  2. Cyst
  3. Drug ineffective
  4. Nephrolithiasis
  5. Pancreatic neuroendocrine tumour
  6. Polyuria

Common Jardiance and Enstilar drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Diabetic ketoacidosis

50-59:

  1. Cyst

60+:

  1. Calculus urinary
  2. Contusion
  3. Joint injury
  4. Limb injury
  5. Lumbar spinal stenosis
  6. Meralgia paraesthetica
  7. Nausea
  8. Nephrolithiasis
  9. Pancreatic neuroendocrine tumour
  10. Polyuria

Common conditions people have *:

  1. Psoriasis (immune-mediated disease that affects the skin): 8 people, 80.00%
  2. Diabetes: 3 people, 30.00%
  3. Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 20.00%
  4. Type 2 Diabetes: 2 people, 20.00%
  5. High Blood Pressure: 2 people, 20.00%
  6. Urination - Painful: 1 person, 10.00%
  7. Blockage Of Leg Arteries: 1 person, 10.00%
  8. Cardiac Failure: 1 person, 10.00%
  9. High Blood Cholesterol: 1 person, 10.00%
  10. Insomnia (sleeplessness): 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Jardiance and Enstilar?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Jardiance and Enstilar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Jardiance interactions:

Browse all interactions between Jardiance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Enstilar interactions:

Browse all interactions between Enstilar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on empagliflozin and betamethasone dipropionate; calcipotriene (the active ingredients of Jardiance and Enstilar, respectively), and Jardiance and Enstilar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Jardiance and Enstilar.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: